Cadila Healthcare rose 2% to Rs 1,015 at 9:18 IST on BSE after the company said it has received the final approval from USFDA to market Clonidine Hcl Injection 0.1 and 0.5 mg/ml, 10 ml in the United States.
The announcement was made after market hours on Monday, 24 February 2014.
Meanwhile, the S&P BSE Sensex was up 78.25 points or 0.38% at 20,889.69.
On BSE, so far 4,007 shares were traded in the counter as against average daily volume of 43,000 shares in the past two weeks.
The stock hit a high of Rs 1,018.95 so far during the day, which is a record high for the counter. The stock hit a low of Rs 1,001.10 so far during the day. The stock had hit a 52-week low of Rs 631 on 20 August 2013.
Clonidine hydrochloride injection is a centrally acting analgesic solution for use in continuous epidural infusion devices which is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.
Also Read
Cadila Healthcare said that the company now has 90 approvals and has so far filed 216 abbreviated new drug applications (ANDAs) since the commencement of filing process in FY 2003-04.
Cadila Healthcare's consolidated net profit jumped 81.5% to Rs 185.97 crore on 17.7% growth in net sales to Rs 1838.04 crore in Q3 December 2013 over Q3 December 2012.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News